At a glance
1
Finished Products
1
Therapy Areas
1+
Delivery Formats
C3-CURA™
Primary Platform
All ingredients
Ingredient · 13/14
Ingredient · 13/14Policosanol
Long-chain aliphatic alcohol
Long-chain aliphatic alcohol
Market Landscape
The opportunity – and where the market falls short.
- 01Lipid modulator – supports LDL reduction and HDL improvement
- 02Cardiovascular support – vascular health, circulation, long-term heart function
- 03Natural alternative to synthetic lipid-lowering agents
- 04Synergistic use with actives like curcumin
- 05Preventive relevance for cardiometabolic management
The Stabicon Edge
From market limitation to measurable transformation.
| Market Limitation | Stabicon Transformation | Impact |
|---|---|---|
| Low Market Awareness | Preventive Positioning – early lipid management | Relevance in proactive cardiovascular care |
| Limited Clinical Positioning | Integrated Cardio-Metabolic Approach | Adoption in wellness and therapeutic segments |
| Format Constraints | Simplified Oral Tablet Formats | Usability and compliance |
| Lack of Combinations | Combination Strategy – Policosanol + Curcumin | Dual-action efficacy |
| Weak Differentiation | Multi-Pathway Value Proposition | Clear product differentiation |
| Missed Preventive Segment | Cardio-Metabolic Portfolio Integration | Scalable preventive portfolio |
Stabicon's Portfolio
Policosanol reimagined across therapy areas and delivery formats.
1 finished formulation powered by Policosanol, organised across 1 therapy category.
01
Products
01
Therapy Areas
01+
Formats
01 · Bladder • Liver • Recovery wellness
Translate